Inventiva (NASDAQ:IVA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Inventiva (NASDAQ:IVA) from a sell rating to a hold rating in a research note issued to investors on Saturday,Wall Street Zen reports.

Other equities analysts also recently issued research reports about the stock. Guggenheim increased their price target on shares of Inventiva from $11.00 to $14.00 and gave the stock a “buy” rating in a research note on Tuesday, September 15th. Piper Sandler restated an “overweight” rating on shares of Inventiva in a report on Wednesday, September 16th. Truist Financial increased their target price on Inventiva from $13.00 to $18.00 and gave the stock a “buy” rating in a research report on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inventiva in a research report on Friday, July 17th. Finally, Cantor Fitzgerald initiated coverage on Inventiva in a report on Friday, July 17th. They issued an “overweight” rating on the stock. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Inventiva presently has an average rating of “Buy” and an average target price of $15.86.

Inventiva Stock Performance

IVA opened at $3.48 on Friday. Inventiva has a 12 month low of $3.11 and a 12 month high of $7.98. The business has a 50-day moving average of $4.30 and a two-hundred day moving average of $4.64.

Inventiva (NASDAQ:IVA) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.14) earnings per share for the quarter. The firm had revenue of $0.75 million for the quarter. Research analysts predict that Inventiva will post -0.81 EPS for the current fiscal year.

Institutional Investors Weigh In On Inventiva

Large investors have recently made changes to their positions in the business. NEXTBio Capital Management LP acquired a new stake in Inventiva in the 4th quarter valued at $6,039,000. Propel Bio Management LLC acquired a new position in shares of Inventiva during the fourth quarter worth about $4,650,000. Eventide Asset Management LLC purchased a new stake in shares of Inventiva in the fourth quarter worth about $1,155,000. Seven Fleet Capital Management LP acquired a new stake in shares of Inventiva in the first quarter valued at about $1,111,000. Finally, Persistent Asset Partners Ltd acquired a new stake in shares of Inventiva in the fourth quarter valued at about $603,000. Institutional investors and hedge funds own 19.06% of the company’s stock.

Inventiva Company Profile

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Dijon, France. The company develops oral small-molecule therapies for chronic metabolic and autoimmune diseases, with a focus on conditions that have limited treatment options.

Inventiva’s lead product candidate is lanifibranor, an investigational pan-PPAR agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease associated with metabolic disorders.